Takeda (TAK) announced the FDA has approved HYQVIA for the treatment of chronic inflammatory demyelinating polyneuropathy as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults. HYQVIA is now available as a maintenance therapy for adult patients with chronic inflammatory demyelinating polyneuropathy in the U.S.
"With the FDA approval of HYQVIA for CIDP, we can now offer a personalized maintenance treatment option for adults with this debilitating disease," said Giles Platford, president of Takeda's Plasma-Derived Therapies Business Unit.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.